Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years. Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well. Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders. Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs. According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.
Peptide is a biologically, naturally or artificially constituted form of amino acid monomers. Peptides can be utilized for treating various gastrointestinal disorders that mostly effect parts of the digestive system such as the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum. Peptides are considered as an effective therapeutic agent for treating gastrointestinal diseases. Owing to their impressive preclinical results, an array of new peptide based gastrointestinal disorder therapeutics are expected to enter the market soon.
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market
In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region. During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.
On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.
Shire plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan plc, Accredo Health Group, Inc., are the key market players profiled in the Fact.MR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio. This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.
Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR
Medical research institutes as well as leading companies in the pharmaceutical industry are ramping up their efforts toward development of profound therapeutic drugs for treating gastrointestinal disorders. This Fact.MR report analyzes the expansion of global peptide based gastrointestinal disorders therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.
The scope of Fact.MR’s report is to analyze the global peptide based gastrointestinal disorders therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Drug manufacturers, research institutes, and raw material suppliers in the global peptide based gastrointestinal disorders therapeutics market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based gastrointestinal disorders therapeutics.
The report commences with a brief information of the global peptide based gastrointestinal disorders therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based gastrointestinal disorders therapeutics market.
The next section offers an overview of the global peptide based gastrointestinal disorders therapeutics market. This comprises an introduction to the market, along with a standard definition of the product – peptide based gastrointestinal disorders therapeutics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.
The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.
In order to offer readers with up-to-date information about the latest advancements in the global peptide based gastrointestinal disorders therapeutics market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide based gastrointestinal disorders therapeutic drugs. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide based gastrointestinal disorders therapeutic drug manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.
The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based gastrointestinal disorders therapeutics market. Drug, distribution channel and region are key segments that define the growth of the global market for peptide based gastrointestinal disorders therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.
The report’s last section comprises of the global peptide based gastrointestinal disorders therapeutics market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide based gastrointestinal disorders therapeutics market.
Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,
- Primary research
- Secondary research
- Trade research
- Focused interviews
- Social media analysis
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.